Repare Therapeutics (NASDAQ:RPTX) Announces Quarterly Earnings Results

Repare Therapeutics (NASDAQ:RPTX) issued its earnings results on Monday. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10, Zacks reports. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%.

Repare Therapeutics Trading Down 1.7 %

Repare Therapeutics stock opened at $1.18 on Monday. The company has a market capitalization of $50.16 million, a P/E ratio of -0.59 and a beta of 0.88. Repare Therapeutics has a 1-year low of $1.06 and a 1-year high of $7.45. The firm’s fifty day simple moving average is $1.26 and its 200-day simple moving average is $2.48.

Analyst Ratings Changes

Several research analysts have weighed in on RPTX shares. Stifel Nicolaus dropped their price objective on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Bloom Burton cut shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a report on Friday, November 8th. Finally, Lifesci Capital reissued a “market perform” rating on shares of Repare Therapeutics in a research report on Friday, December 13th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.